<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AGOMELATINE" rxcui="306718">
<ATC code="N06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of agomelatine, with risk of increase of the undesirable effects.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clozapine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLANZAPINE" rxcui="61381">
<ATC code="N05AH03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the olanzapine, with risk of increase of the undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIRFENIDONE" rxcui="88221">
<ATC code="L04AX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of pirfenidone with signs of overdose</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline) </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
